

For your NYHA Class II patients with an Ejection Fraction of $\leq 40\%$

Pr **ENTRESTO**[®]

To reduce the incidence of heart failure hospitalization and CV death^{1,2}

ENTRESTO[®] (sacubitril/valsartan) is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalization.¹

ENTRESTO[®] should be administered in combination with other heart failure therapies, in place of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB).¹ Consult the ENTRESTO[®] Product Monograph at www.novartis.ca/EntrestoMonograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-363-8883.

References: 1. ENTRESTO[®] Product Monograph. Novartis Pharmaceuticals Canada Inc. October 24, 2017. 2. McMurray JJ, Packer M, Desai AS *et al.* Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;371:993-1004.

 **NOVARTIS**

Novartis Pharmaceuticals Canada Inc.
Dorval (Quebec) H9S 1A9
www.novartis.ca
Tel: 514-631-6775 Fax: 514-631-1867

Entresto is a registered trademark.
© 2019 Novartis Pharmaceuticals Canada Inc.
PRO/ENT/0199E



 Pr **Entresto**[®]
sacubitril/valsartan